No Data
No Data
Revolution Medicines Is Maintained at Overweight by Barclays
Revolution Medicines Is Maintained at Overweight by
Express News | Revolution Medicines Inc. : Barclays Raises Target Price to $54 From $52
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $54
Barclays analyst Peter Lawson maintains $Revolution Medicines(RVMD.US)$ with a buy rating, and adjusts the target price from $52 to $54.According to TipRanks data, the analyst has a success rate of 44
Barclays Remains a Buy on Revolution Medicines (RVMD)
UBS Adjusts Price Target on Revolution Medicines to $65 From $40, Maintains Buy Rating
Revolution Medicines (RVMD) has an average buy rating and price target range of $52 to $73, according to analysts polled by Capital IQ.Price: 46.05, Change: -0.72, Percent Change: -1.54
Express News | Revolution Medicines Inc : Guggenheim Raises Target Price to $72 From $50